Fisher Bret L, Potvin Rick
Eye Center of North Florida, Panama City, FL, USA.
Science in Vision, Akron, NY, USA.
Clin Ophthalmol. 2016 Jul 18;10:1297-303. doi: 10.2147/OPTH.S112080. eCollection 2016.
To compare the relative effectiveness of a Tri-Moxi-Vanc intraocular solution injected transzonularly into the vitreous with the topical formulation of Pred-Moxi-Ketor (given for the first week postoperatively) followed by Pred-Ketor (given for weeks 2-4 after surgery).
This was a single-site, single-surgeon, prospective, randomized, subject-masked contralateral eye study with an active comparator and was approved by an appropriate ethics committee. Twenty-five subjects with uncomplicated cataract who were scheduled for cataract surgery were enrolled. If surgery was uneventful, subjects received either an injection in that eye or followed a minimum drop postoperative pharmaceutical regimen. The second eye surgery was performed with the opposite treatment. Subjects were followed for 1 month. Measures of interest were the changes in intraocular pressure (IOP) from baseline and the changes in corneal and macular thickness. Subjects were also asked to evaluate pain perception, visual quality, and overall satisfaction with surgery. They were also asked which regimen they preferred.
IOP was not statistically significantly different between the groups (P=0.81); there was also no statistically significant difference in IOP over time (P=0.74). There was no statistically significant difference in central macular thickness at 1 week and 1 month between the groups (P=0.18). The central corneal thickness was significantly greater 1 day postoperatively relative to baseline, but there was no statistically significant difference between the groups at any time point (P=0.92). The difference in reported pain was also not statistically significantly different between the groups (P=0.67). Satisfaction with surgery was similar for both groups, but significantly more subjects preferred the injection for overall experience (P<0.01).
Cataract surgery completed with the two pharmaceutical regimens was similar in outcome. Significantly more subjects preferred the injection, presumably as a function of the greater convenience with no apparent difference in the therapeutic effect.
比较经睫状体平坦部向玻璃体腔内注射三联莫西-万古霉素眼内溶液与术后第一周给予Pred-Moxi-Ketor局部制剂（之后2至4周给予Pred-Ketor）的相对有效性。
这是一项单中心、单术者、前瞻性、随机、受试者遮蔽对侧眼研究，设有活性对照，已获适当伦理委员会批准。纳入25例计划行白内障手术的单纯性白内障患者。若手术顺利，受试者在该眼接受注射或遵循最低限度的术后滴眼药物方案。对侧眼手术采用相反治疗。对受试者随访1个月。感兴趣的指标包括眼压相对于基线的变化以及角膜和黄斑厚度的变化。还要求受试者评估疼痛感受、视觉质量以及对手术的总体满意度。此外，询问他们更喜欢哪种方案。
两组之间眼压无统计学显著差异（P = 0.81）；眼压随时间也无统计学显著差异（P = 0.74）。两组在1周和1个月时中央黄斑厚度无统计学显著差异（P = 0.18）。术后1天中央角膜厚度相对于基线显著增加，但在任何时间点两组之间均无统计学显著差异（P = 0.92）。两组之间报告的疼痛差异也无统计学显著意义（P = 0.67）。两组对手术的满意度相似，但明显更多受试者在总体体验方面更喜欢注射治疗（P < 0.01）。
两种药物方案完成的白内障手术结果相似。明显更多受试者更喜欢注射治疗，推测是因为其便利性更高且治疗效果无明显差异。
